

Dr Camelia Quek PhD, BAdvSci, DipMolBiotech

CINSW Research Fellow | Postdoctoral Scientist, Oncology Bioinformatics

Melanoma Institute Australia and The University of Sydney

Email: camelia.quek@melanoma.org.au / camelia.quek@sydney.edu.au

T: +61 2 86276228 | Twitter: @cameliaquek | LinkedIn: <https://au.linkedin.com/in/cameliaquek>

PROFESSIONAL EXPERIENCE

- 2021 – Present CINSW Early Career Research Fellow
- 2016 – Present Postdoctoral Scientist (Oncology Bioinformatics) – Melanoma Institute Australia, The University of Sydney
- 2016 Clinical Laboratory Coordinator – The Kirby Institute, University of New South Wales
- 2011 – 2012 Research Officer – Institute of Molecular and Cell Biology, A*STAR Biopolis, Singapore

EDUCATION AND HONOURS

- 2012 – 2016 Doctor of Philosophy in Medicine and Health Science, The University of Melbourne (Sawyer Medal in Outstanding PhD and Melbourne Research Scholar)
- 2009 – 2011 Bachelor of Advanced Science (Hons Class 1) – Major in Molecular Biology, University of New South Wales (University Medal and Golden Jubilee Scholar)
- 2006 – 2009 Diploma in Molecular Biotechnology with Merit, Nanyang Polytechnic (Gold Medal)

PROFESSIONAL DEVELOPMENT AND ACHIEVEMENTS

Grants and fellowship

- 2021 – 2024 Cancer Institute New South Wales Early Career Research Fellowship
- 2020 The University of Sydney – Charles Perkins Centre Early- and Mid-Career Researchers Seed Funding Award – CIA
- 2020 Sydney Catalyst Pilot and Seed Funding Award – CIC
- 2020 CLEARbridge Foundation – AI
- 2019 – 2022 NHMRC Grant – AI

Awards

- 2018 Best Poster – IAP (International Academy of Pathology) conference 2018, New South Wales, Australia.
- 2017 NSW Premier's Awards for Outstanding Cancer Research (Excellence in Translational Research to MIA Research Team) - Dr Camelia Quek, Australia
- 2017 Sawyer Medal in Outstanding Research Achievements by Department of Biochemistry and Molecular Biology PhD students, The University of Melbourne, Australia

2017	Most Outstanding Oral Presentation – Anti-Cancer Agents and Drug Development 1 session, The University of Sydney Cancer Research Network 2017 Postgraduate & ECR Cancer Research Symposium, Australia (AUD\$200)
2017	Best Poster – Immunotherapy@Brisbane Conference, Australia (AUD\$200)
2014	Poster Prize Winner – Wellcome Trust Computational RNA Biology Conference, Hinxton, United Kingdom (one-year F1000 membership and £1000 F1000 manuscript waiver)
2011	University Medal in Molecular Biology, University of New South Wales, Australia
2011	Undergraduate Student Encouragement Award, University of New South Wales, Australia (Australian Society for Microbiology NSW-ACT)
2009	Gold Medal in Molecular Biotechnology, Nanyang Polytechnic, Singapore

Scholarships

2017	Cancer Research Network Early Career Researcher Conference Travel Scholarship, Australia
2017	European Association for Cancer Research Meeting Bursary for Cancer Genomics, United Kingdom
2017	Immunotherapy@Brisbane 2017 Travel Scholarship, Australia
2017	Melanoma Institute Australia Conference and Travel Fund for Early Career Researcher, Australia
2015	Global Young Scientists Summit Travel Scholarship, GYSS @ One-north, Singapore
2014	Wellcome Trust Travel Bursary, United Kingdom
2014	European Molecular Biology Laboratory (EMBL) Australia PhD Symposium Travel Scholarship, Australia
2014	Victorian Life Sciences Computation Initiative Travel, Workshop and Conference Scholarship
2014	Bio21 Institute PhD Travel Scholarship
2014	The University of Melbourne Abroad Travel Scholarship
2014	The University of Melbourne Department of Biochemistry and Molecular Biology Travel Scholarship
2012	Winter School in Mathematics & Computational Biology Travel Scholarship, The University of Queensland, Australia
2012	Melbourne International Research Scholarship, The University of Melbourne
2012	Melbourne International Fee Remission Scholarship, The University of Melbourne
2009 – 2011	Golden Jubilee Scholarship, University of New South Wales

Teaching

- 20016 – Present Supervisor and mentor for PhD, Honours, MD-PhD students – The University of Sydney (2x Honours student awarded High Distinction Score and 2x completed PhD students with merit)
- 2015 Scientist Mentor – Gene Technology Access Centre
- 2012 – 2015 Teaching Assistant – Department of Biochemistry and Molecular Biology, The University of Melbourne
- 2013 University Tutor – Faculty of Medicine, The University of Melbourne

Scientific contributions and volunteer activities

- 2021 – Present Special Guest Editor for Genes Journal
- 2020 – Present Steering committee member – Cancer Research Network
- 2020 – Present Editorial Reviewer – Frontiers in Oncology
- 2016 – Present Reviewer (Melanoma Research, International Journal of Molecular Sciences, Targeted Oncology, Parkinsonism & Related Disorders, Melanoma Research, Australian Medical Student Journal)
- 2016 – Present Grant Reviewer – CINSW, NHMRC and CRN Grant Workshop
- 2016 – Present Ambassador – European Association Cancer Research (EACR)
- 2016 – Present Participate in Melanoma March Sydney
- 2016 – 2018 Sydney Representative – COMBINE (The Australian Bioinformatics And Computational Biology Society and International Society for Computational Biology)
- 2016 – 2017 Sponsorship (co-lead) – Australian Society for Medical Research New South Wales
- 2016 – 2017 Participate as event helper in Walk 4 Brain Cancer Manly for Cure Brain Cancer Foundation
- 2015 – 2019 Abstract Reviewer – Australian Society for Medical Research Student Research Symposium Victoria
- 2017 – 2019 Organising Committee – Sydney Bioinformatics Research Symposium
- 2015 Conference Assistant – ComBio2015
- 2013 – 2015 Student Research Symposium Organiser – The Australian Society for Medical Research
- 2013 – 2014 Treasurer – Biochemists And Molecular Biologists at the Bio21 Institute (BAMBII), The University of Melbourne

Professional memberships and roles

- 2017 – Present European Association for Cancer Research (Ambassador), COMBINE (Sydney Representative), American Society of Clinical Oncology, American Association for Cancer Research, Cancer Research Network - The University of Sydney, Sydney Vital Translation Caner Research, Sydney Catalyst, , Australian Bioinformatics And Computational Biology Society, F1000 Premier Research

REFEREES

Professor Richard Scolyer (Fellowship supervisor)
Royal Prince Alfred Hospital
Clinical Professor, Sydney Medical School, The University of Sydney
Conjoint Medical Director, Melanoma Institute Australia
Tissue Pathology & Diagnostic Oncology
Royal Prince Alfred Hospital
Missenden Road Camperdown NSW 2050 Australia
Telephone: +61 2 9515 7011
Email: richard.scolyer@health.nsw.gov.au

Professor Andrew Francis Hill (PhD project supervisor)
La Trobe Institute for Molecular Science
La Trobe University
Bundoora, VIC 3086, Australia
Tel: +61 3 9479 1224
Email: andrew.hill@latrobe.edu.au

Dr. Chol-Hee Jung (PhD bioinformatics supervisor)
Melbourne Bioinformatics
187 Grattan Street
Carlton, Melbourne
Victoria 3053
Tel: +61 3 9035 5822
Email: jungch@unimelb.edu.au

PUBLICATIONS

*co-first authors

1. **Quek C**, Bai X, Long GV, Scolyer RA, Wilmott JS. High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy. **Genes** **2021**; Oct;12(10):1629.
 2. Wu, S.Z., Roden, D.L., Al-Eryani, G., Bartonicek, N., Harvey, K., Cazet, A.S., Chan, C.-L., Junankar, S., Hui, M.N., Millar, E.A., Beretov, J., Horvath, L., Joshua, A.M., Stricker, P., Wilmott, J.S., **Quek, C.**, Long, G.V., Scolyer, R.A., Yeung, B.Z., Segara, D., Mak, C., Warriar, S., Powell, J.E., O'Toole, S., Lim, E. and Swarbrick, A. Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. **Genome Medicine** **2021**; 13, 1-17.
 3. da Silva, I.P., Lo, S., **Quek, C.**, Gonzalez, M., Carlino, M.S., Long, G.V., and Menzies, A.M. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. **Cancer** **2020**; 126, 86-97.
 4. Gide, T.N.*, **Quek, C.***, Menzies, A.M., Tasker, A.T., Shang, P., Holst, J., Madore, J., Lim, S.Y., Velickovic, R., Wongchenko, M., Yan, Y., Lo, S., Carlino, M. S., Guminski, A., Saw, R. P. M., Pang, A., McGuire, H. M., Palendira, U., Thompson, J. F., Rizos, H., Silva, I. P. D., Batten, M., Scolyer, R. A., Long, G. V., and Wilmott, J. S. (2019). Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. **Cancer Cell** **2019**; 35, 238-255. e236.
 5. **Quek, C.**, Rawson, R. V., Ferguson, P. M., Shang, P., Silva, I., Saw, R. P., Shannon, K., Thompson, J. F., Hayward, N. K., and Long, G. V. (2019). Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal
-

-
- mucosal melanoma identified in a study of 27 Australian mucosal melanomas. *Oncotarget* **2019**; 10, 930-941.
6. Zhao, W., Cheng, L., **Quek, C.**, Bellingham, S.A., and Hill, A.F. Novel miR-29b target regulation patterns are revealed in two different cell lines. *Scientific reports* **2019**; 9, 1-17.
 7. House, I. G., Savas, P., Lai, J., Chen, A. X. Y., Oliver, A. J., Teo, Z. L., Todd, K. L., Henderson, M. A., Giuffrida, L., Petley, E. V., Sek, K., Mardiana, S., Gide, T. N., **Quek, C.**, Scolyer, R. A., Long, G. V., Wilmott, J. S., Loi, S., Darcy, P. K., and Beavis, P. A. Macrophage derived CXCL9 and CXCL10 are required for anti-tumor immune responses following immune checkpoint blockade. *Clinical Cancer Research* **2019**, clincanres.1868.2019.
 8. Edwards, J., Tasker, A., da Silva, I. P., **Quek, C.**, Batten, M., Ferguson, A., Allen, R., Allanson, B., Saw, R. P., and Thompson, J. F. Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials. *Clinical Cancer Research* **2019**; 25, 3247-3258.
 9. Gide, T. N., Silva, I. P., Quek, C., Ahmed, T., Menzies, A. M., Carlino, M. S., Saw, R. P., Thompson, J. F., Batten, M., Long, G. V., Scolyer, R.A. and Wilmott, J.S. Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. *Oncotimmunology* **2019**; 1659093.
 10. Wilmott, J.S., Johansson, P.A., Newell, F., Waddell, N., Ferguson, P., Quek, C., Patch, A.-M., Nones, K., Shang, P., Pritchard, A.L., Kazakoff, S., Holmes, O., Leonard, C., Wood, S., Xu, Q., Saw, R.P.M., Spillane, A.J., Stretch, J.R., Shannon, K.F., Kefford, R.F., Menzies, A.M., Long, G.V., Thompson, J.F., Pearson, J.V., Mann, G.J., Hayward, N.K. and Scolyer, R.A. Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. *International journal of cancer* **2019**; 144, 1049-1060.
 11. Lee, H., **Quek, C.**, Silva, I., Tasker, A., Batten, M., Rizos, H., Lim, S. Y., Nur Gide, T., Shang, P., Attrill, G. H., Madore, J., Edwards, J., Carlino, M. S., Guminski, A., Saw, R. P. M., Thompson, J. F., Ferguson, P. M., Palendira, U., Menzies, A. M., Long, G. V., Scolyer, R. A., and Wilmott, J. S. Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. *Oncoimmunology* **2019**; 8, e1537581.
 12. da Silva, I. P., Wang, K. Y., Wilmott, J. S., Holst, J., Carlino, M. S., Park, J. J., **Quek, C.**, Wongchenko, M., Yan, Y., and Mann, G. Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma. *Clinical Cancer Research* **2019**; 25, 1272-1279.
 13. Zhao, X., Little, P., Hoyle, A. P., Pegna, G. J., Hayward, M. C., Ivanova, A., Parker, J. S., Marron, D. L., Soloway, M. G., Jo, H., Salazar, A. H., Papakonstantinou, M. P., Bouchard, D. M., Jefferys, S. R., Hoadley, K. A., Ollila, D. W., Frank, J. S., Thomas, N. E., Googe, P. B., Ezzell, A. J., Collichio, F. A., Lee, C. B., Earp, H. S., Sharpless, N. E., Hugo, W., Wilmott, J. S., **Quek, C.**, Waddell, N., Johansson, P. A., Thompson, J. F., Hayward, N. K., Mann, G. J., Lo, R. S., Johnson, D. B., Scolyer, R. A., Hayes, D. N., and Moschos, S. J. The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. *Front Oncol* **2018**; 8, 584.
 14. Lamoury, FM, Hajarizadeh B, Soker A, Martinez D, **Quek C**, Cunningham P, Catlett B, Cloherty GA, Marks P, Amin J, Grebely J, Dore GJ, Applegate TL. "Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried-Blood Spot Samples." *The Journal of Molecular Diagnostics* **2018**; 20(5): 621-627.
 15. Edwards J, Wilmott JS, Madore J, Gide T, **Quek C**, Tasker A, Ferguson A, Chen J, Hewavisenti R, Hersey P, Gebhardt T, Weninger W, Britton W, Saw R, Thompson J, Menzies AM, Long GV, Scolyer RA, Palendira U. "CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy naive
-

-
- melanoma patients and expand significantly during anti-PD1 treatment." *Clinical Cancer Research* **2018**; 24, 3036-3045.
16. Lamoury, FM, Hajarizadeh B, Soker A, Martinez D, **Quek C**, Cunningham P, Catlett B, Cloherty GA, Marks P, Amin J, Grebely J, Dore GJ, Applegate TL. "Hepatitis C virus core antigen and dried blood spots as simplified hepatitis C virus diagnostic tools." *Journal of Hepatology* **2017**; 66(1), p.S710.
17. **Quek C***, Bellingham SA *, Jung CH, Scicluna B, Shambrook MC, Sharples RA, Cheng L, Hill AF. "Defining the purity of exosomes required for diagnostic profiling of small RNA suitable for biomarker discovery." *RNA Biology* **2017**; 14(2): 245-258.
[DOI: 10.1080/15476286.2016.1270005][PMID: 28005467]
18. **Quek C**, Hill AF. "The role of extracellular vesicles in neurodegenerative diseases." *Biochemical and Biophysical Research Communications* **2017**; 483(4): 1178-1186.
[DOI: 10.1016/j.bbrc.2016.09.090][PMID: 27659705]
19. **Quek C**, Pham ST, Kieu TB, Pham TT, Luu LBN, Le TKT, Pham VH. "H. pylori resistance to antibiotics and clarithromycin: Results from the study on 193 strains isolated from Vietnamese patients with gastro-duodenal ulcer." *Vietnamese Journal of Gastroenterology* **2016**; 9(45):2872.
20. **Quek C**, Pham ST, Tran KT, Pham BT, Huynh LV, Luu NBL, Le TKT, Quek K, Pham VH. "Antimicrobial susceptibility and clarithromycin resistance patterns of Helicobacter pylori clinical isolates in Vietnam." *F1000 Research* **2016**; 5:671.
[DOI: 10.12688/f1000research.8239.1][PMID: 27583131]
21. **Quek C***, Cheng L*, Hung LW*, Sharples RA, Sherratt NA, Barnham KJ, Hill AF. "Gene dysregulation is restored in the Parkinson's disease MPTP neurotoxic mice model upon treatment of the therapeutic drug Cull(atsm)." *Nature Scientific Reports* **2016**; 6:22398.
[DOI:10.1038/srep22398][PMID: 26928495]
22. **Quek C**, Jung CH, Bellingham SA, Lonie A, Hill AF. "iSRAP – a one-touch research tool for rapid profiling of small RNA-seq data" *Journal of Extracellular Vesicles* **2015**; 4(1):29454.
[DOI: <http://dx.doi.org/10.3402/jev.v4.29454>]
23. Pathan M, Keerthikumar S, Ang CS, Gangoda L, **Quek C**, Williamson NA, Mouradov D, Sieber OM, Simpson RJ, Basic A, Hill AF, Stroud DA, Ryan MT, Agbinya, JI, Burgess AW, Mathivanan S. "FunRich: An open access standalone functional enrichment and interaction network analysis tool." *Proteomics* **2015**; 15(15):2597-2601.
[DOI: 10.1002/pmic.201400515] [PMID: 25921073]
24. Cheng L, **Quek C**, Sun X, Bellingham SA, Hill AF. "The detection of microRNA associated with Alzheimer's disease in biological fluids using next-generation sequencing technologies" *Frontiers in Genetics* **2013**; 4:150.
[DOI:10.3389/fgene.2013.00150] [PMID: 23964286]
-

Selected National and International Conference Presentations

1. **Quek C**, Silva I, Al-Eryani G, Aaron Mayer A, Bartonicek N, Harvey K, Buckley C, Braubach O, Saw R, Stretch J, Shannon K, Menzies A, Scolyer R, Long G, Swarbrick A, Wilmott J. Spatially resolved single-cell sequencing reveals unfavourable immune diversity and intratumoural vessels in resistance melanoma patients treated with checkpoint inhibitor immunotherapy. **European Association for Cancer Research Bioinformatics in Cancer 2021**, Virtual Event, Worldwide. **Oral Abstract; Proffered Paper 1**
2. **Quek C**, Silva I, Al-Eryani G, Aaron Mayer A, Bartonicek N, Harvey K, Buckley C, Braubach O, Saw R, Stretch J, Shannon K, Menzies A, Scolyer R, Long G, Swarbrick A, Wilmott J. CODEX highly multiplex image

-
- mapping to CITE-seq datasets reveal the spatial dynamics of the TME during the development of acquired resistant in anti-PD-1 and CTLA-4 treated melanoma. **American Association for Cancer Research 2021**, United States of America.
3. **Quek C**, Bai X, Shang P, Attrill GH, Gide TN, Ferguson PM, Nahar K, Umaimainthan Palendira U, Long GV, Scolyer RA and Wilmott JS. Identifying and targeting novel immunosuppressive driver mechanisms in adolescent and young adult (AYA) melanoma patients. **Society for Melanoma Research 2021**, Virtual Event, Worldwide. **Oral Abstract**
 4. **Quek C**, Bai X, Shang P, Attrill GH, Gide TN, Ferguson PM, Nahar K, Umaimainthan Palendira U, Long GV, Scolyer RA and Wilmott JS. Immunosuppressive features in young melanoma patients treated with checkpoint-based immunotherapies. **Sydney Cancer Conference 2021**, Virtual Event, Worldwide. **Oral Abstract; Proffered Paper 96**
 5. **Quek C**, Bai X, Shang P, Attrill GH, Gide TN, Ferguson PM, Nahar K, Umaimainthan Palendira U, Long GV, Scolyer RA and Wilmott JS. Immunosuppressive-driven mechanisms impede response to checkpoint-based immunotherapies in adolescent and young adult melanoma patients. **Sydney Catalyst Research Conference 2021**, Sydney, Australia. **Oral Abstract**
 6. **Quek C**, Gide T, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, Yan Y, Lo S, Carlino MS, Guminski A, Saw R, Silva I, Pang A, McGuire HM, Palendira U, John F. Thompson JF, Rzos H, Batten M, Scolyer RA, Long GV and Wilmott JS. "Anti-PD-1 Monotherapy versus Combined Anti-PD-1 and Anti-CTLA-4 Immunotherapy in Metastatic Melanoma: Who Will Benefit?" **Immuno-Oncology Summit Europe 2020**, London, United Kingdom. **Invited Speaker**
 7. **Quek C**. "Who Will Benefit from Anti-PD-1 Monotherapy versus Combined Anti-PD-1 and Anti-CTLA-4 Immunotherapy in Metastatic Melanoma" **Sydney Catalyst Seminar 2020**, New South Wales, Australia. **Invited Speaker**
 8. **Quek C**. "Anti-PD-1-based Immunotherapies in Metastatic Melanoma" **Sydney Vital Cancer Research Event 2020**, New South Wales, Australia. **Invited Speaker**
 9. **Quek C**, Gide T, Madore J, Menzies A, Dent R, Wongchenko M, Yan Y, Carlino M, Guminski A, Saw R, Thompson J, Long G, Scolyer R, Wilmott J. "Anti-PD-1 monotherapy versus combination anti-PD-1 and anti-CTLA-4 therapy in metastatic melanoma". **Sydney Catalyst Postgraduate and Early Career Research Symposium 2018**, New South Wales, Australia. **Oral Abstract**
 10. **Quek C**, Shang P, Rawson R, Ferguson P, Saw R, Long G, Mann G, Scolyer R, Wilmott J. "Recurrent hotspot sf3b1 mutations in mucosal melanoma: frequency and impact on survival." **IAP (International Academy of Pathology) conference 2018**, New South Wales, Australia. **Best Poster awarded**
 11. **Quek C**, Gide T, Madore J, Menzies A, Dent R, Wongchenko M, Yan Y, Carlino M, Guminski A, Saw R, Thompson J, Long G, Scolyer R, Wilmott J. "Anti-PD-1 monotherapy versus combination anti-PD-1 and anti-CTLA-4 therapy in metastatic melanoma: who will benefit?". **The University of Sydney Cancer Research Network Postgraduate & ECR Cancer Research Symposium 2017**, New South Wales, Australia. **Best Oral Presentation awarded**
 12. **Quek C**, Gide T, Madore J, Menzies A, Dent R, Wongchenko M, Yan Y, Carlino M, Guminski A, Saw R, Thompson J, Long G, Scolyer R, Wilmott J. "Gene expression profiling to predict responsiveness and resistance to anti-PD-1 immunotherapy in metastatic melanoma." **3rd EACR Conference on Cancer Genomics 2017**, Cambridge, United Kingdom. **EACR Meeting Bursary awarded**
 13. **Quek C**, Gide T, Madore J, Menzies A, Dent R, Wongchenko M, Yan Y, Carlino M, Guminski A, Saw R, Thompson J, Long G, Scolyer R, Wilmott J. "Identifying gene signatures that are clinically relevant to

-
- response of anti-PD- immunotherapy in metastatic melanoma." *Immunotherapy@Brisbane Conference 2017*, Queensland, Australia. **Best poster presentation and travel bursary awarded**
14. Gide TN, **Quek C**, Madore J, Menzies AM, Dent R, Carlino MS, Guminski A, Saw R, Thompson JF, Wilmott JS, Scolyer RA, Long GV. "Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy." *ASCO-SITC Clinical Immuno-Oncology Symposium 2017*, Florida, United States of America.
15. **Quek C**, Gide TN, Madore J, Menzies AM, Dent R, Carlino MS, Guminski A, Saw R, Thompson JF, Wilmott JS, Scolyer RA, Long GV. "RNA-seq analysis on metastatic melanoma patients treated with anti-PD-1 immunotherapy". *Melanoma Research Meeting 2016*, New South Wales, Australia. **Oral Abstract**
16. **Quek C**, Jung CH, Bellingham SA, Lonie A, Hill AF. "iSRAP: A one-touch research tool for rapid profiling of small RNA-seq data." *EMBL Australia 2nd Student Symposium 2015*, Victoria, Australia.
17. **Quek C**, Bellingham SA, Jung CH, Scicluna B, Sharples RA, Cheng L, Hill AF. "Rapid profiling of exosomal small RNA expression in neurodegenerative diseases." *1st Australian Neurodegeneration and Dementia Conference 2015*, Victoria, Australia.
18. **Quek C**, Jung CH, Bellingham SA, Lonie A, Hill AF. "iSRAP: An integrated research tool for analysing small RNA-seq data." *Global Young Scientists Summit 2015*, Nanyang Technological University, Singapore. **Travel grant awarded**
19. **Quek C**, Bellingham SA, Jung CH, Scicluna B, Sharples RA, Cheng L, Hill AF. "Rapid profiling of exosomal small RNA expression in neurodegenerative diseases." *Computational RNA Biology Conference 2014*, Wellcome Trust, Hinxton, United Kingdom. **Best poster presentation and meeting bursary awarded**
20. **Quek C**, Jung CH, Bellingham SA, Lonie A, Hill AF. "iSRAP: An integrated research tool for analysing small RNA-seq data." *Next Generation Sequencing Workshop 2014*, Wellcome Trust, Hinxton, United Kingdom.
21. **Quek C**, Bellingham SA, Jung CH, Scicluna B, Sharples RA, Cheng L, Hill AF. "An integrated pipeline for benchtop sequencing to rapidly profile small non-coding RNA expression levels in exosomes from mouse neuronal models." *EMBL Australia 1st Student Symposium 2014*, New South Wales, Australia. **Oral Abstract**
22. **Quek C**, Bellingham SA, Jung CH, Scicluna B, Sharples RA, Cheng L, Hill AF. "Rapid profiling of exosomal small RNA expression in neurodegenerative diseases". *Australasia Extracellular Vesicles Conference 2014*, Queensland, Australia. **Oral Abstract**
23. **Quek C**, Bellingham SA, Jung CH, Scicluna B, Sharples RA, Cheng L, Hill AF. "Rapid profiling of exosomal small RNA expression in neurodegenerative diseases." *16th EMBL PhD Symposium 2014*, Heidelberg, Germany. **EMBL Travel Scholarship awarded**
24. **Quek C**, Bellingham SA, Jung CH, Scicluna B, Sharples RA, Cheng L, Hill AF. "Profiling of small RNA in neuronal-derived exosomes using high performance technologies." *Curie Institute Science Seminar 2014*, Paris, France. **Invited Speaker**
25. Cheng L, Bellingham SA, Sun CX, **Quek C**, Coleman BM, Masters CL, Hill AF. "Deep sequencing of exosomal microRNA associated with Alzheimer's disease." *2nd International Meeting of ISEV 2013*, Boston, United States of America.